C4 Therapeutics (CCCC) News Today → A ‘DeFi Summer’ Projected! (From Crypto 101 Media) (Ad) Free CCCC Stock Alerts $6.00 -0.11 (-1.80%) (As of 02:08 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 6:49 AM | americanbankingnews.comC4 Therapeutics (NASDAQ:CCCC) Price Target Raised to $8.00 at Wells Fargo & CompanyMay 13 at 4:44 AM | americanbankingnews.comC4 Therapeutics (NASDAQ:CCCC) Price Target Raised to $14.00 at Stifel NicolausMay 13 at 4:09 AM | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), ACADIA Pharmaceuticals (ACAD) and Disc Medicine (IRON)May 13 at 2:42 AM | americanbankingnews.comC4 Therapeutics, Inc. to Post Q2 2024 Earnings of ($0.42) Per Share, Brookline Capital Management Forecasts (NASDAQ:CCCC)May 12, 2024 | americanbankingnews.comBrookline Capital Management Weighs in on C4 Therapeutics, Inc.'s FY2027 Earnings (NASDAQ:CCCC)May 10, 2024 | finance.yahoo.comC4 Therapeutics Inc (CCCC) Q1 2024 Earnings: Navigating Challenges with Strategic CollaborationsMay 10, 2024 | marketbeat.comC4 Therapeutics, Inc. to Post FY2027 Earnings of $15.91 Per Share, Brookline Capital Management Forecasts (NASDAQ:CCCC)C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) - Equities research analysts at Brookline Capital Management raised their FY2027 earnings per share (EPS) estimates for C4 Therapeutics in a research note issued to investors on Wednesday, May 8th. Brookline Capital Management analyst L. Cann nowMay 9, 2024 | markets.businessinsider.comC4 Therapeutics: Hold Rating Maintained Amidst Encouraging Drug Progress and Stable FinancialsMay 9, 2024 | markets.businessinsider.comKey Takeaways From C4 Therapeutics Analyst RatingsMay 9, 2024 | marketbeat.comC4 Therapeutics (NASDAQ:CCCC) Given New $8.00 Price Target at Wells Fargo & CompanyWells Fargo & Company boosted their target price on shares of C4 Therapeutics from $7.00 to $8.00 and gave the stock an "equal weight" rating in a research report on Thursday.May 9, 2024 | americanbankingnews.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 8, 2024 | investorplace.comCCCC Stock Earnings: C4 Therapeutics Misses EPS, Misses Revenue for Q1 2024May 8, 2024 | globenewswire.comC4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsApril 30, 2024 | finanznachrichten.deC4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 29, 2024 | globenewswire.comC4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 14, 2024 | marketbeat.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) have earned an average recommendation of "Moderate Buy" from the six ratings firms that are covering the company, Marketbeat reports. Three analysts have rated the stock with a hold rating and three have issued a buy rating on the coApril 11, 2024 | marketbeat.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Up 73.0% in MarchC4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) saw a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 9,150,000 shares, an increase of 73.0% from the March 15th total of 5,290,000 shares. Based on an average daily trading volume, of 3,740,000 shares, the days-to-cover ratio is currently 2.4 days.April 11, 2024 | seekingalpha.comArvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win SituationApril 9, 2024 | globenewswire.comC4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology ForumApril 8, 2024 | msn.comC4 Dips on Release of DataApril 8, 2024 | finance.yahoo.comC4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024April 8, 2024 | globenewswire.comC4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024March 29, 2024 | marketbeat.comPublic Employees Retirement System of Ohio Lowers Position in C4 Therapeutics, Inc. (NASDAQ:CCCC)Public Employees Retirement System of Ohio decreased its position in C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 65.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 71,163 sharMarch 28, 2024 | marketbeat.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Sees Significant Increase in Short InterestC4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the target of a significant increase in short interest in March. As of March 15th, there was short interest totalling 5,290,000 shares, an increase of 78.1% from the February 29th total of 2,970,000 shares. Based on an average daily volume of 4,830,000 shares, the days-to-cover ratio is presently 1.1 days.March 28, 2024 | marketbeat.comC4 Therapeutics (NASDAQ:CCCC) Shares Down 2% C4 Therapeutics (NASDAQ:CCCC) Shares Down 2%March 28, 2024 | finance.yahoo.comHere’s Why Meridian Small Cap Growth Fund Trimmed C4 Therapeutics (CCCC)March 20, 2024 | marketbeat.comC4 Therapeutics (NASDAQ:CCCC) Trading Down 3.9%C4 Therapeutics (NASDAQ:CCCC) Trading Down 3.9%March 19, 2024 | marketbeat.comC4 Therapeutics (NASDAQ:CCCC) Trading Up 7.3%C4 Therapeutics (NASDAQ:CCCC) Stock Price Up 7.3%March 18, 2024 | marketbeat.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Sees Significant Drop in Short InterestC4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the recipient of a large decrease in short interest during the month of February. As of February 29th, there was short interest totalling 2,970,000 shares, a decrease of 6.6% from the February 14th total of 3,180,000 shares. Based on an average trading volume of 15,210,000 shares, the days-to-cover ratio is currently 0.2 days.March 16, 2024 | finance.yahoo.comCCCC Mar 2024 17.000 callMarch 16, 2024 | finance.yahoo.comCCCC Mar 2024 10.000 putMarch 14, 2024 | marketbeat.comC4 Therapeutics (NASDAQ:CCCC) Stock Price Down 6.8%C4 Therapeutics (NASDAQ:CCCC) Trading Down 6.8%March 9, 2024 | nasdaq.comGuru Fundamental Report for CCCCMarch 6, 2024 | marketbeat.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Shares Sold by Acadian Asset Management LLCAcadian Asset Management LLC trimmed its holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 78.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 28,014 shares of the company's stock after selling 100,046 sharesMarch 5, 2024 | globenewswire.comC4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024March 5, 2024 | marketbeat.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest UpdateC4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the target of a significant drop in short interest in February. As of February 15th, there was short interest totalling 3,180,000 shares, a drop of 5.1% from the January 31st total of 3,350,000 shares. Based on an average daily volume of 14,840,000 shares, the short-interest ratio is presently 0.2 days.March 4, 2024 | globenewswire.comC4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic ProteinsMarch 2, 2024 | finance.yahoo.comCCCC Mar 2024 9.000 callMarch 1, 2024 | seekingalpha.comC4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains StretchedFebruary 28, 2024 | marketbeat.comC4 Therapeutics (NASDAQ:CCCC) Hits New 12-Month High at $10.83C4 Therapeutics (NASDAQ:CCCC) Hits New 52-Week High at $10.83February 27, 2024 | finance.yahoo.comNew Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)February 26, 2024 | markets.businessinsider.comBreaking Down C4 Therapeutics: 4 Analysts Share Their ViewsFebruary 26, 2024 | marketbeat.comC4 Therapeutics (NASDAQ:CCCC) Given New $8.00 Price Target at Morgan StanleyMorgan Stanley lifted their price objective on C4 Therapeutics to $8.00 and gave the company an "equal weight" rating in a research report on Monday.February 25, 2024 | finance.yahoo.comCCCC Mar 2024 8.500 putFebruary 24, 2024 | ca.finance.yahoo.comCCCC Mar 2024 7.000 putFebruary 24, 2024 | finance.yahoo.comC4 Therapeutics Full Year 2023 Earnings: Misses ExpectationsFebruary 23, 2024 | markets.businessinsider.comStrong Financials and Promising Drug Pipeline Bolster Buy Rating for C4 TherapeuticsFebruary 23, 2024 | realmoney.thestreet.comC4 Therapeutics price target raised by $1 at Stifel, here's whyFebruary 23, 2024 | marketbeat.comC4 Therapeutics (NASDAQ:CCCC) Earns Buy Rating from Stifel NicolausStifel Nicolaus reissued a "buy" rating and set a $13.00 price target (up previously from $12.00) on shares of C4 Therapeutics in a research report on Friday.February 22, 2024 | benzinga.comC4 Therapeutics Stock (NASDAQ:CCCC) Insider Trades Get C4 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter. Email Address Charles Payne Demystifies Options (Ad)When it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free. CCCC Media Mentions By Week CCCC Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CCCC News Sentiment▼0.640.55▲Average Medical News Sentiment CCCC News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CCCC Articles This Week▼203▲CCCC Articles Average Week Get C4 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Editas Medicine News Today Taysha Gene Therapies News Today Adaptive Biotechnologies News Today Voyager Therapeutics News Today iTeos Therapeutics News Today Lexeo Therapeutics News Today Fate Therapeutics News Today Allogene Therapeutics News Today Alvotech News Today Alector News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CCCC) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Drop BOMBSHELL June 13th?Paradigm PressRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldElon to Transform U.S. Economy? Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityThe most important AI company you've never heard ofManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyWATCH: The Truth About InflationBirch Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
